Finally, to prove the validity of SGK1 inhibition in treating human arrhythmia disorders, we demonstrated the efficacy of SGK1 inhibitor in shortening the action potential duration in human iPSC-derived cardiomyocytes from a patient with known LQT3 due to a gain-of-function mutation in NaV1.5. This evidence concerns the gene SCN5A and long QT syndrome 3.